about
Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenzaUse of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.Oral oseltamivir in human experimental influenza B infection.Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis.Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial.Oral oseltamivir treatment of influenza in children.The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection.Safety and pharmacology of oseltamivir in clinical use.Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine ((18)F) PET/CT.Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate CancerPharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.Clinical benefits with oseltamivir in treating influenza in adult populations : results of a pooled and subgroup analysis.Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration studyThe pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysisPilot study of the efficacy of atevirdine in the treatment of AIDS dementia complexEffect of age and gender on tirilazad pharmacokinetics in humansSmoking and DNA damage in cervical cells
P50
Q28146066-F575365E-5CC7-46BC-8FDD-013AA52237DDQ30304330-A5D87C21-C268-424B-A64D-5BF35CA3B8C0Q30306367-F893145C-B9C6-4B7D-8F42-F63729A8C0C1Q30312048-331EE97B-32E3-4B7E-9182-BAB8AFE1677DQ31931976-D85B2F67-E8BD-4A4E-BBDA-A9F06E226498Q32064242-FD2B742B-75B6-4C99-B9D8-0621E2F4AE32Q33956427-2606A7D1-EAC2-43C9-AE89-A095644B9B53Q34217769-CC83FE7D-3E9C-41FB-99EA-7113691B4399Q34942946-35C9259E-2647-4B50-97AD-D1B733E49999Q35196192-C7F83C13-99B1-479B-B317-55DEA6B1D403Q38849160-D71BE6BD-15E4-4993-AB62-5A8B2229EF67Q42379563-BB95EDF5-E2B2-49E6-9ABC-AAFA69F800CEQ44544248-1C274B56-5517-4CC2-BC1F-AE3ADB5D3E70Q46306590-8AAC8AD4-EFDE-4975-A885-C85416F94DBAQ48719424-ED44696A-A063-4575-AF9E-4FF1F8F9BB06Q58874870-656B0E94-64F7-4E9A-9DF8-159AFFD8C1E0Q58874874-1F5D2D1E-3D46-4402-BFE2-E86E29E9EEDAQ58874902-D68FA843-052C-453F-88DD-90A870B96DE1Q58874903-0C800FBC-BD1E-4764-A2F8-8780F011F40FQ58874904-C5876CBB-1E89-42DC-96DF-FEBC2083C76C
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
P Ward
@nl
Penelope Ward
@en
Penelope Ward
@es
type
label
P Ward
@nl
Penelope Ward
@en
Penelope Ward
@es
prefLabel
P Ward
@nl
Penelope Ward
@en
Penelope Ward
@es
P106
P31
P496
0000-0002-7585-4313